Market Overview

Syros to Present at 2018 Wedbush PacGrow Healthcare Conference


Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company
pioneering the development of medicines that control the expression of
genes, today announced that its Chief Financial Officer Joseph J. Ferra
will present a corporate overview at the 2018 Wedbush PacGrow Healthcare
Conference. Details are as follows:

2018 Wedbush PacGrow Healthcare Conference
Date: Wednesday,
August 15
Presentation Time: 10:20 a.m. ET
Location: Parker
New York 119 West 56th St., New York, NY

A live webcast of the presentation will be available on the Investors &
Media section of the Syros website at
An archived replay will be available for approximately 30 days following
the presentation.

About Syros Pharmaceuticals
Syros is pioneering the
understanding of the non-coding region of the genome to advance a new
wave of medicines that control expression of genes. Syros has built a
proprietary platform that is designed to systematically and efficiently
analyze this unexploited region of DNA in human disease tissue to
identify and drug novel targets linked to genomically defined patient
populations. Because gene expression is fundamental to the function of
all cells, Syros' gene control platform has broad potential to create
medicines that achieve profound and durable benefit across a range of
diseases. Syros is currently focused on cancer and monogenic diseases
and is advancing a growing pipeline of gene control medicines. Syros'
lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2
clinical trial for genomically defined subsets of patients with acute
myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective
CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced
solid tumors. Led by a team with deep experience in drug discovery,
development and commercialization, Syros is located in Cambridge, Mass.

View Comments and Join the Discussion!